Navigation Links
Paragon BioTeck, Inc. Announces FDA Approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10%

Tigard, OR (PRWEB) March 22, 2013

Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10%, to dilate the pupil.

“This approval represents an important milestone not only for Paragon, but also within the eye care community as a whole,” said Patrick Witham, President and CEO of Paragon BioTeck. “Phenylephrine Hydrochloride Ophthalmic Solution has been marketed without FDA approval for decades, and during that time has been administered to millions of patients. With the increase in drug manufacturers domestically and abroad, FDA oversight over drug products is more important than ever. The FDA approval process is in place to ensure both that a drug is safe and that it’s manufactured under appropriate controls and oversight.”

About Phenylephrine Hydrochloride Ophthalmic Solution
Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% is an alpha-1 adrenergic receptor agonist used for dilation of the pupil due to its vasoconstrictor and mydriatic action. Phenylephrine possesses predominantly a-adrenergic effects. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic by constricting ophthalmic blood vessels and the radial muscle of the iris.

Phenylephrine Hydrochloride Ophthalmic Solution Important Safety Information
Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is contraindicated in patients with hypertension or thyrotoxicosis, as well as in pediatric patients under the age of one due to the increased risk of systemic toxicity. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients. It’s for topical ophthalmic use only, and not for injection.

Serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions, some fatal, and significant elevations in blood pressure have been reported. Caution is advised in pediatric patients less than five years of age, and in patients with elevated blood pressure, cardiovascular disease or hyperthyroidism. Blood pressure should be monitored in patients with cardiovascular or endocrine disease. Rebound miosis has been reported one day after instillation.

Ocular adverse reactions include eye pain and stinging on instillation, temporary blurred vision and photophobia. Cardiovascular adverse reactions include increase in blood pressure, syncope, myocardial infarction, tachycardia, arrhythmia and subarachnoid hemorrhage.

About Paragon BioTeck, Inc.
Paragon BioTeck is a privately held ophthalmic-focused biopharmaceutical and medical device company pursuing the development and commercialization of products addressing unmet medical needs in the fight to protect and preserve eyesight. For more information on the company and its work, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces Price Match Guarantee for Comparable Medical Weight Loss Plans
2. Number One Provider of Hearing Aids in Medford OR, Imaginears, Announces Launch of New Website
3. Sharon Kleyne Announces Investment into Fresh Water IP Technology
4. Manatee Works Announces Second Generation Mobile Decoding Engine
5. Depression Treatment Announces 2013 Blog Award Winners
6. Cornell Dubilier Announces Long-Life Ultracapacitors
7. MyoNatural Announces New Offer for Chiropractors and Doctors Offices Around the US
8. MinuteHound Announces Time and Attendance Solutions for Fitness Centers and Chains
9. La Jolla Vein Care Announces that Nisha Bunke-Paquette, M.D., FACPh, Inducted As a Fellow Of The American College Of Phlebology
10. NLN Foundation for Nursing Education Announces 2013 Nursing Education Scholarship Program Promoting Academic Progression
11. Dennis R. Hill MD Announces Launch of High Dose Rate Brachytherapy of Prostate Cancer Website
Post Your Comments:
(Date:11/28/2015)... ... 2015 , ... Safe storage for contraceptive devices may not always be easy ... Jersey and the other from Bradley Beach, New Jersey, there is an easy solution ... having to replace NuvaRings more often than necessary. As such, it affords peace of ...
(Date:11/27/2015)... Los Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... the conversation at the recent 2015 American Dental Association meeting in Washington D.C. revolved ... can help protect a patient’s overall health. The talk stressed the link between periodontal ...
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in ... (see Table 1-1 ). More than 3.7 billion people under the age of ... 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection . , "The ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in ... for mental health and wellness consultation, has collaborated with a leading web-based marketplace ... knowledge gap experienced by parents and bring advice from parenting experts within their ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... --> ... att använda SyMRI för att hitta optimal ... med multipel skleros (MS) eller hjärntumörmetastaser och ... för att kunna använda SyMRI Research Edition ... kan man generera flera konstrastbilder från en ...
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Italian Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
Breaking Medicine Technology: